JORDAN ANDREW R 4
4 · IDERA PHARMACEUTICALS, INC. · Filed Sep 30, 2022
Insider Transaction Report
Form 4
JORDAN ANDREW R
Chief Strategy Officer
Transactions
- Award
Series Z Convertible Preferred Stock
2022-09-28+6,843→ 6,843 total→ Common Stock (6,843,000 underlying) - Award
Common Stock, par value $0.001
2022-09-28+651,364→ 651,364 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock").
- [F2]Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations.